Article
Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio
Rating:
0.0
Views:
84
Likes:
1
Library:
1
Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the drugmaker to growth.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value